Analysis of sulfated polysaccharides
The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.
1. A method of analyzing an unfractionated heparin sample to correlate a structural or chemical property of the unfractionated heparin sample with a patient reaction comprising:
providing a first structural signature that includes the identity and number of monosaccharide and disaccharide building blocks and the linkages between the monosaccharide and disaccharide building blocks of polysaccharides of a first unfractionated heparin sample determined using one or more methods chosen from the group consisting of matrix laser desorption/ionization mass spectroscopy (MALDI-MS), electrospray ionization mass spectroscopy (ESI-MS), capillary electroporesis (CE), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), fluorometry, enzyme-linked immunosorbent assay (ELISA), and nuclear magnetic resonance (NMR), wherein the first unfractionated heparin sample or an unfractionated heparin sample having the same structural signature as the first unfractionated heparin sample is correlated with a patient reaction of edema or systemic allergic reaction;
providing a second structural signature that includes the identity and number of monosaccharide and disaccharide building blocks and the linkages between monosaccharide and disaccharide building blocks of polysaccharides of a second unfractionated heparin sample determined using one or more methods chosen from the group consisting of matrix laser desorption/ionization mass spectroscopy (MALDI-MS), electrospray ionization mass spectroscopy (ESI-MS), capillary electroporesis (CE), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), fluorometry, enzyme-linked immunosorbent assay (ELISA), and nuclear magnetic resonance (NMR), wherein the second unfractionated heparin sample or an unfractionated heparin sample having the same structural signature as the second unfractionated heparin sample is not correlated with a patient reaction of edema or systemic allergic reaction, and wherein the first unfractionated heparin sample and the second unfractionated heparin sample are isolated from porcine intestinal mucosa;
comparing the first and second structural signatures to identify a chemical or structural property of a polysaccharide correlated with a patient reaction of edema or systemic allergic reaction, to thereby analyze the heparin sample.
2. The method of claim 1 , wherein the method further comprises selecting an unfractionated heparin sample based upon the absence of the chemical or structural property.
3. The method of claim 1 , further comprising discarding an unfractionated heparin sample based upon the presence of the chemical or structural property.
4. The method of claim 1 , wherein the patient reaction is edema.
5. The method of claim 4 , wherein the edema is peripheral edema.
6. The method of claim 1 , wherein the patient reaction is systemic allergic reaction.
7. The method of claim 6 , wherein the systemic allergic reaction is an anaphylactoid reaction.
8. The method of claim 1 , wherein the chemical or structural property is a polysaccharide having a structure that does not naturally exist in unfractionated heparin.
9. The method of claim 1 , wherein the structural signatures are determined by one or more methods chosen from the group consisting of CE, NMR and HPLC.